Shire announced that it has not received an approach from Takeda
Japan firm is believes that possible transaction with Shire will help the company to advance its strategy for Vision 2025.
The deal will help Takeda to expand its presence in therapeutic areas such as oncology, GI and neuroscience, and further enhance its R&D strategy on crucial therapeutic areas.
The transaction will also add Takeda with Shire’s global rare disease franchise, which will strengthen its expertise in producing specialized medicines.
Shire’s acquisition will also allow Takeda to strengthen its large-molecule focused late-stage pipeline within its core therapeutic areas, enabling to enhance Takeda’s own pipeline and discovery capabilities.
Takeda further added that the deal will balance its geographic focus to align with the market opportunity in the US and drive financial value from a combined financial profile.
Takeda is engaged in the research and development activities in therapeutic areas, including oncology, gastroenterology and neuroscience. It is also involved in the development of vaccines.
Shire products are available across therapeutic areas, including hematology, immunology, neuroscience, lysosomal storage disorders. The company markets its products in more than 100 countries.
In January this year, Takeda has offered to acquire Belgium-based cell therapy company TiGenix for €520m to expand its late-stage gastroenterology pipeline and its footprint in the US specialty care market.
The Japanese pharma firm said that the deal reinforces its commitment to patients with Inflammatory Bowel Disease (IBD), which currently has limited treatment options.
The acquisition will also extend Takeda's existing collaboration with TiGenix, aimed at introducing new treatment options for gastrointestinal disorders.
Image: Takeda Midosuji Building, the head office of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Photo: courtesy of J o/Wikipedia.org.